Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Curr Res Transl Med
; 66(3): 87-89, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-30191811
ABSTRACT
Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with standard treatment. Idelalisib, a delta-isoform specific Phosphatidyl-inositol-3-kinase (PI3K) inhibitor has shown its efficacy in other hematopoietic B malignancies. We report the case of a 51-years old patient with relapsed and refractory Hodgkin's Lymphoma receiving idelalisib after several regimens of chemotherapy. He achieved a good partial response for several months, unfortunately, idelalisib had to be stopped because of the onset of a severe polyradiculoneuritis attributed to this treatment. We assume here that the polyradiculoneuritis could be caused by T cell mediated autoimmunity to myelin proteins. To our knowledge, this adverse event has never been described so far with idelalisib.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polirradiculopatia
/
Purinas
/
Doença de Hodgkin
/
Quinazolinonas
Tipo de estudo:
Diagnostic_studies
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Curr Res Transl Med
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
França